JP2007501859A5 - - Google Patents

Download PDF

Info

Publication number
JP2007501859A5
JP2007501859A5 JP2006532943A JP2006532943A JP2007501859A5 JP 2007501859 A5 JP2007501859 A5 JP 2007501859A5 JP 2006532943 A JP2006532943 A JP 2006532943A JP 2006532943 A JP2006532943 A JP 2006532943A JP 2007501859 A5 JP2007501859 A5 JP 2007501859A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
aryl
cycloalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501859A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/014671 external-priority patent/WO2004101562A2/en
Publication of JP2007501859A publication Critical patent/JP2007501859A/ja
Publication of JP2007501859A5 publication Critical patent/JP2007501859A5/ja
Pending legal-status Critical Current

Links

JP2006532943A 2003-05-13 2004-05-11 γ−セクレターゼ阻害剤としての架橋n−アリールスルホニルピペリジン Pending JP2007501859A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47014603P 2003-05-13 2003-05-13
PCT/US2004/014671 WO2004101562A2 (en) 2003-05-13 2004-05-11 Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors

Publications (2)

Publication Number Publication Date
JP2007501859A JP2007501859A (ja) 2007-02-01
JP2007501859A5 true JP2007501859A5 (https=) 2007-06-28

Family

ID=33452372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006532943A Pending JP2007501859A (ja) 2003-05-13 2004-05-11 γ−セクレターゼ阻害剤としての架橋n−アリールスルホニルピペリジン

Country Status (14)

Country Link
US (1) US7368457B2 (https=)
EP (1) EP1641801B9 (https=)
JP (1) JP2007501859A (https=)
CN (1) CN1820010A (https=)
AR (1) AR044294A1 (https=)
AT (1) ATE401328T1 (https=)
CA (1) CA2525124A1 (https=)
CL (1) CL2004001011A1 (https=)
DE (1) DE602004015110D1 (https=)
ES (1) ES2308206T3 (https=)
MX (1) MXPA05012268A (https=)
PE (1) PE20050555A1 (https=)
TW (1) TW200510405A (https=)
WO (1) WO2004101562A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PE20060481A1 (es) * 2004-06-30 2006-06-19 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas
BRPI0614944A2 (pt) * 2005-08-19 2011-04-26 Elan Pharm Inc inibidores sulfonamido n-bicìclicos ponte de gama-secretase
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
AR076936A1 (es) * 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2013096744A1 (en) 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EA038942B1 (ru) 2012-08-28 2021-11-12 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA035500B1 (ru) 2013-05-17 2020-06-25 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Hbv感染の治療のための併用療法
WO2015118057A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015131773A1 (zh) * 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HK1259410A1 (zh) 2015-09-29 2019-11-29 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2007501859A5 (https=)
JP2012510523A5 (https=)
JP2004516314A5 (https=)
JP2020530487A5 (https=)
JP2018519357A5 (https=)
RU2003133448A (ru) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс- хемокинового рецептора
RU2013156074A (ru) Диазакарбазолы и способы применения
JP2010514786A5 (https=)
JP2017526726A5 (https=)
JP2008074862A5 (https=)
JP2009519218A5 (https=)
JP2005508905A5 (https=)
JP2021527051A5 (https=)
JP2006512313A5 (https=)
JP2008510691A5 (https=)
JP2009534404A5 (https=)
JP2006528205A5 (https=)
JP2007516180A5 (https=)
JP2007526257A5 (https=)
JP2009529540A5 (https=)
JP2008533191A5 (https=)
JP2009534405A5 (https=)
JP2018529650A5 (https=)
JP2014521625A5 (https=)
JP2010511721A5 (https=)